The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL. The Food and Drug Administration has approved ...

Tecartus (brexucabtagene autoleucel), an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was approved for adult patients 18 years of age and older with relapsed or refractory ...

In the poster being presented, patients treated with the pivotal dose of Tecartus in the pooled analysis Phase 1 and 2 (n=78), the median follow-up time was 53.6 months (range 44.7-82.3 ...

The agency states that the letters “notify manufacturers of each such licensed product to update the package insert to include available information ... Carvykti, Kymriah, Tecartus, and Yescarta. 1 ...

Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19 ...

2.1 Brexucabtagene autoleucel (Tecartus, Kite) is indicated for 'the treatment of adult patients 26 years of age and above with relapsed or refractory B cell precursor acute lymphoblastic leukaemia'.

CHMP backed the CAR T cell therapy for the treatment of mantle cell lymphoma back in October Kite, a Gilead company, has announced that its chimeric antigen receptor (CAR) T cell therapy Tecartus has ...